Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Elicio Therapeutics Inc.
ELTX | US
4.94
USD0.01
0.20%
ELTX | US
About Elicio Therapeutics Inc.
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
21/10/2024
Close
4.94
Open
4.93
High
4.95
Low
4.72
Elicio Therapeutics Inc. a clinical-stage biotechnology company engages in developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases. The company's lead product candidate is ELI-002 an AMP therapeutic vaccine for the treatment of KRAS-driven cancers. It is also developing ELI-004 an AMP-modified CpG adjuvant a component of ELI-002 to treat or prevent a range of diseases; ELI-003 for cancers involving an ALK mutation; ELI-011 for hematological cancers; ELI-005 a product for the prevention of COVID-19; and ELI-002 7P (AMPLIFY-7P) a vaccine for mutated solid tumors. The company's AMP platform enables to develop differentiated treatment modalities including therapeutic vaccines adjuvants and cell therapy AMPlifiers. The company was formerly known as VEDANTRA PHARMACEUTICALS INC. and changed its name to Elicio Therapeutics Inc. on September 18 2019. The company was incorporated in 2011 and is headquartered in Boston Massachusetts.
View LessELTX | US
Risk
67.0
Sharpe
-0.27
Luna's Score
46/100
Recommendation
Hold
Luna says (ELTX | US)
What's Working
Strength based on increasing price with high volume
Low Debt to Equity (< 0.25)
What's not Working
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Rich in Valuation (Price to Book > 8)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
60.4%1 month
67.0%3 months
84.2%6 months
102.4%Returns
Fundamental Ratios
PE
5.18
Fwd. PE
-
Price to book
10.11
Debt to equity
-3.89
Debt to assets
0.41
Ent. to EBITDA
-2.61
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-41.00M
MarketCap
51.72M
MarketCap(USD)
51.72M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-353.02
Short ratio
2.36
Short perc.
0.45
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
0.62
Range1M
0.75
Range3M
1.79
Volumes: Market Activity
Rel. volume
1.14
Price X volume
80.25K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -2.61 | - | Cheaper |
| Ent. to Revenue | - | - | - |
| PE Ratio | 5.18 | 41.03 | Cheaper |
| Price to Book | 10.11 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 84.18 | - | Par |
| Debt to Equity | -3.89 | -1.23 | Cheaper |
| Debt to Assets | 0.41 | 0.25 | Expensive |
| Market Cap | 51.72M | - | Emerging |
